Premium
P4‐535: PRESENTATION OF A ROUTINE‐USE PRE‐ANALYTICAL PROCEDURE FOR AD CSF BIOMARKERS
Author(s) -
Hansson Oskar,
Stomrud Erik,
Andreasson Ulf,
Zetterberg Henrik,
Bauer Ekaterina,
Haehl Teresa,
Logan Chad A.,
Rutz Sandra,
Wahl Simone,
Weinberger Jan-Philipp,
Blennow Kaj
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.08.082
Subject(s) - cerebrospinal fluid , biomarker , medicine , lumbar puncture , clinical practice , normal pressure hydrocephalus , protocol (science) , chromatography , pathology , chemistry , disease , biochemistry , dementia , alternative medicine , family medicine
Background: There are even a few potential candidate genes that convey the risk of developing AD. A promising gene has been identified as Brain-derived Neurotrophic Factor (BDNF). (Kao 2012). The relationship between BDNF and AD is still being determined, but multiple studies have found that there is some form of link between the two. In fact, significant evidence suggests that BDNF is associated with AD. (Sen 2017). This is because neurotrophic factors are proteins that regulate several aspects of cognitive operations. They are essential in memory formation and cognition, atonal guidance, cell morphology and neuronal survival. Neurotrophic factors have received a great deal of attention in Alzheimer’s research because of these roles. (O’Bryant 2011). The purpose is to compare multiple BDNF genotypes and memory loss and/or diagnosis in humans who have shown early signs of decline. The genotypes of BDNF include Val/Val, Val/Met, and Met/Met. Currently, the appearance of the Met trait will diagnose the potential development of AD. This hypothesis has not been proven to date and that is the main goal of this project. Methods: One hundred and fifty subjects aged 50þ, 100 with impaired memory and 50 with normal memory, participated in this study. Demography and history, cognitive assessments, and biospecimen collection – buccal/saliva swab were collected. Samples were redacted. The results were not disclosed to the subjects. Results: Memory Impaired subjects did not show a statistical difference among the VAL/VAL, VAL/MET, and MET/MET genotypes. There was a trend in low MMSE and MET carriers. 92 patients with memory impairment and 50 subjects with normal memory were included. memory impaired 62 VAL/ VAL, 25 VAL/MET, and 5 MET/MET normal memory 31 VAL/ VAL, 17 VAL/MET, and 2 MET/MET Chi Square 0.62654. Conclusions: the sample size was small but the statistics offered evidence that BDNF alleles are not different in the memory impaired or normal people the research is centered around AD which is only one of many cognitive diseases it is possible that other illnesses could potentially use BDNF as a possible biomarker BDNF alone may not be a marker but due to the complexity of these type of diseases a combination of other proteins along with BDNF could actually be used as a biomarker Further investigation is needed in order to find an accurate marker for AD.